Cargando…
Concise Review: Stem Cell Therapy for Stroke Patients: Are We There Yet?
Four decades of preclinical research demonstrating survival, functional integration, and behavioral effects of transplanted stem cells in experimental stroke models have provided ample scientific basis for initiating limited clinical trials of stem cell therapy in stroke patients. Although safety of...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708064/ https://www.ncbi.nlm.nih.gov/pubmed/31099181 http://dx.doi.org/10.1002/sctm.19-0076 |
_version_ | 1783445942289039360 |
---|---|
author | Borlongan, Cesario V. |
author_facet | Borlongan, Cesario V. |
author_sort | Borlongan, Cesario V. |
collection | PubMed |
description | Four decades of preclinical research demonstrating survival, functional integration, and behavioral effects of transplanted stem cells in experimental stroke models have provided ample scientific basis for initiating limited clinical trials of stem cell therapy in stroke patients. Although safety of the grafted cells has been overwhelmingly documented, efficacy has not been forthcoming. Two recently concluded stroke clinical trials on mesenchymal stem cells (MSCs) highlight the importance of strict adherence to the basic science findings of optimal transplant regimen of cell dose, timing, and route of delivery in enhancing the functional outcomes of cell therapy. Echoing the Stem Cell Therapeutics as an Emerging Paradigm for Stroke and Stroke Treatment Academic Industry Roundtable call for an NIH‐guided collaborative consortium of multiple laboratories in testing the safety and efficacy of stem cells and their derivatives, not just as stand‐alone but preferably in combination with approved thrombolytic or thrombectomy, may further increase the likelihood of successful fruition of translating stem cell therapy for stroke clinical application. The laboratory and clinical experience with MSC therapy for stroke may guide the future translational research on stem cell‐based regenerative medicine in neurological disorders. stem cells translational medicine 2019;8:983&988 |
format | Online Article Text |
id | pubmed-6708064 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67080642019-08-28 Concise Review: Stem Cell Therapy for Stroke Patients: Are We There Yet? Borlongan, Cesario V. Stem Cells Transl Med Tissue Engineering and Regenerative Medicine Four decades of preclinical research demonstrating survival, functional integration, and behavioral effects of transplanted stem cells in experimental stroke models have provided ample scientific basis for initiating limited clinical trials of stem cell therapy in stroke patients. Although safety of the grafted cells has been overwhelmingly documented, efficacy has not been forthcoming. Two recently concluded stroke clinical trials on mesenchymal stem cells (MSCs) highlight the importance of strict adherence to the basic science findings of optimal transplant regimen of cell dose, timing, and route of delivery in enhancing the functional outcomes of cell therapy. Echoing the Stem Cell Therapeutics as an Emerging Paradigm for Stroke and Stroke Treatment Academic Industry Roundtable call for an NIH‐guided collaborative consortium of multiple laboratories in testing the safety and efficacy of stem cells and their derivatives, not just as stand‐alone but preferably in combination with approved thrombolytic or thrombectomy, may further increase the likelihood of successful fruition of translating stem cell therapy for stroke clinical application. The laboratory and clinical experience with MSC therapy for stroke may guide the future translational research on stem cell‐based regenerative medicine in neurological disorders. stem cells translational medicine 2019;8:983&988 John Wiley & Sons, Inc. 2019-05-16 /pmc/articles/PMC6708064/ /pubmed/31099181 http://dx.doi.org/10.1002/sctm.19-0076 Text en © 2019 The Author. stem cells translational medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Tissue Engineering and Regenerative Medicine Borlongan, Cesario V. Concise Review: Stem Cell Therapy for Stroke Patients: Are We There Yet? |
title | Concise Review: Stem Cell Therapy for Stroke Patients: Are We There Yet? |
title_full | Concise Review: Stem Cell Therapy for Stroke Patients: Are We There Yet? |
title_fullStr | Concise Review: Stem Cell Therapy for Stroke Patients: Are We There Yet? |
title_full_unstemmed | Concise Review: Stem Cell Therapy for Stroke Patients: Are We There Yet? |
title_short | Concise Review: Stem Cell Therapy for Stroke Patients: Are We There Yet? |
title_sort | concise review: stem cell therapy for stroke patients: are we there yet? |
topic | Tissue Engineering and Regenerative Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708064/ https://www.ncbi.nlm.nih.gov/pubmed/31099181 http://dx.doi.org/10.1002/sctm.19-0076 |
work_keys_str_mv | AT borlongancesariov concisereviewstemcelltherapyforstrokepatientsarewethereyet |